Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Dec;41(12):2754–2756. doi: 10.1128/aac.41.12.2754

Antiviral drug susceptibility of human herpesvirus 8.

J Neyts 1, E De Clercq 1
PMCID: PMC164202  PMID: 9420052

Abstract

We studied the susceptibility of human herpesvirus 8 (HHV-8) to a number of antiherpesvirus agents. The acyclic nucleoside phosphonate (ANP) analogs cidofovir and HPMPA [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)adenine] effected potent inhibition of HHV-8 DNA synthesis, with 50% effective concentrations (EC50) of 6.3 and 0.6 microM, respectively. Adefovir, an ANP with both antiretrovirus and antiherpesvirus activity, blocked HHV-8 DNA replication at a fourfold-lower concentration than did foscarnet (EC50 of 39 and 177 microM, respectively). The most potent inhibitory effect was obtained with the N-7-substituted nucleoside analog S2242 (EC50, 0.11 microM). The nucleoside analogs acyclovir, penciclovir, H2G ((R)-9-[4-hydroxy-2-(hydroxymethyl) butyl]guanine), and brivudine had weak to moderate effects (EC50 of > or =75, 43, 42, and 24 microM, respectively, and EC90 of > or =75 microM), whereas ganciclovir elicited pronounced anti-HHV-8 activity (EC50, 8.9 microM).

Full Text

The Full Text of this article is available as a PDF (150.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrei G., Snoeck R., Reymen D., Liesnard C., Goubau P., Desmyter J., De Clercq E. Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus. Eur J Clin Microbiol Infect Dis. 1995 Apr;14(4):318–329. doi: 10.1007/BF02116525. [DOI] [PubMed] [Google Scholar]
  2. Cesarman E., Nador R. G., Aozasa K., Delsol G., Said J. W., Knowles D. M. Kaposi's sarcoma-associated herpesvirus in non-AIDS related lymphomas occurring in body cavities. Am J Pathol. 1996 Jul;149(1):53–57. [PMC free article] [PubMed] [Google Scholar]
  3. Chang Y., Cesarman E., Pessin M. S., Lee F., Culpepper J., Knowles D. M., Moore P. S. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994 Dec 16;266(5192):1865–1869. doi: 10.1126/science.7997879. [DOI] [PubMed] [Google Scholar]
  4. Cundy K. C., Barditch-Crovo P., Walker R. E., Collier A. C., Ebeling D., Toole J., Jaffe H. S. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother. 1995 Nov;39(11):2401–2405. doi: 10.1128/aac.39.11.2401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Decker L. L., Shankar P., Khan G., Freeman R. B., Dezube B. J., Lieberman J., Thorley-Lawson D. A. The Kaposi sarcoma-associated herpesvirus (KSHV) is present as an intact latent genome in KS tissue but replicates in the peripheral blood mononuclear cells of KS patients. J Exp Med. 1996 Jul 1;184(1):283–288. doi: 10.1084/jem.184.1.283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gao S. J., Kingsley L., Hoover D. R., Spira T. J., Rinaldo C. R., Saah A., Phair J., Detels R., Parry P., Chang Y. Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med. 1996 Jul 25;335(4):233–241. doi: 10.1056/NEJM199607253350403. [DOI] [PubMed] [Google Scholar]
  7. Glesby M. J., Hoover D. R., Weng S., Graham N. M., Phair J. P., Detels R., Ho M., Saah A. J. Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. J Infect Dis. 1996 Jun;173(6):1477–1480. doi: 10.1093/infdis/173.6.1477. [DOI] [PubMed] [Google Scholar]
  8. Humphrey R. W., O'Brien T. R., Newcomb F. M., Nishihara H., Wyvill K. M., Ramos G. A., Saville M. W., Goedert J. J., Straus S. E., Yarchoan R. Kaposi's sarcoma (KS)-associated herpesvirus-like DNA sequences in peripheral blood mononuclear cells: association with KS and persistence in patients receiving anti-herpesvirus drugs. Blood. 1996 Jul 1;88(1):297–301. [PubMed] [Google Scholar]
  9. Jones J. L., Hanson D. L., Chu S. Y., Ward J. W., Jaffe H. W. AIDS-associated Kaposi's sarcoma. Science. 1995 Feb 24;267(5201):1078–1079. doi: 10.1126/science.7855583. [DOI] [PubMed] [Google Scholar]
  10. Kedes D. H., Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest. 1997 May 1;99(9):2082–2086. doi: 10.1172/JCI119380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Morfeldt L., Torssander J. Long-term remission of Kaposi's sarcoma following foscarnet treatment in HIV-infected patients. Scand J Infect Dis. 1994;26(6):749–752. doi: 10.3109/00365549409008645. [DOI] [PubMed] [Google Scholar]
  12. Nador R. G., Cesarman E., Chadburn A., Dawson D. B., Ansari M. Q., Sald J., Knowles D. M. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood. 1996 Jul 15;88(2):645–656. [PubMed] [Google Scholar]
  13. Neyts J., Andrei G., Snoeck R., Jähne G., Winkler I., Helsberg M., Balzarini J., De Clercq E. The N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine is a potent and selective inhibitor of herpesvirus replication. Antimicrob Agents Chemother. 1994 Dec;38(12):2710–2716. doi: 10.1128/aac.38.12.2710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Neyts J., Jähne G., Andrei G., Snoeck R., Winkler I., De Clercq E. In vivo antiherpesvirus activity of N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine. Antimicrob Agents Chemother. 1995 Jan;39(1):56–60. doi: 10.1128/aac.39.1.56. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Neyts J., Snoeck R., Balzarini J., De Clercq E. Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro. Antiviral Res. 1991 Jul;16(1):41–52. doi: 10.1016/0166-3542(91)90057-x. [DOI] [PubMed] [Google Scholar]
  16. Renne R., Zhong W., Herndier B., McGrath M., Abbey N., Kedes D., Ganem D. Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med. 1996 Mar;2(3):342–346. doi: 10.1038/nm0396-342. [DOI] [PubMed] [Google Scholar]
  17. Snoeck R., Andrei G., Gérard M., Silverman A., Hedderman A., Balzarini J., Sadzot-Delvaux C., Tricot G., Clumeck N., De Clercq E. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). Clin Infect Dis. 1994 Apr;18(4):570–578. doi: 10.1093/clinids/18.4.570. [DOI] [PubMed] [Google Scholar]
  18. Zhong W., Wang H., Herndier B., Ganem D. Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6641–6646. doi: 10.1073/pnas.93.13.6641. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES